Skip to main content
. 2013 Feb 26;34(17):1279–1291. doi: 10.1093/eurheartj/eht055

Figure 2.

Figure 2

Trial profile: Flow of participants through the trial. Participants receiving simvastatin 40 mg (with total cholesterol <3.5 mmol/L) or ezetimibe/simvastatin 10/40 mg prior to screening entered the active ER niacin/laropiprant phase of the run-in immediately after the screening visit. *Participants may have more than one reason for being excluded.